Sagimet Biosciences Inc Series A Common Stock

Yahoo Finance • 11 days ago

Sagimet Biosciences GAAP EPS of -$0.40 misses by $0.01

* Sagimet Biosciences press release [https://seekingalpha.com/pr/20305884-sagimet-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate] (SGMT [https://seekingalpha.com/symbol/SGMT]): Q3 GAAP EPS of -$0.40 misse... Full story

Yahoo Finance • 12 days ago

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Ascletis announced completion of... Full story

Yahoo Finance • last month

Sagimet rises after denifanstat succeeds in late stage trial

[Genetic engineering concept. Medical science. Scientific Laboratory.] metamorworks/iStock via Getty Images * Sagimet Biosciences (NASDAQ:SGMT [https://seekingalpha.com/symbol/SGMT]) announced positive results from a late-stage trial of... Full story

Yahoo Finance • last month

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of its pre-NDA consultati... Full story

Yahoo Finance • last month

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, toda... Full story

Yahoo Finance • 2 months ago

Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero

Viking Therapeutics (NASDAQ:VKTX [https://seekingalpha.com/symbol/VKTX]) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed t... Full story

Yahoo Finance • 2 months ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, for development in acne SAN MATEO,... Full story

Yahoo Finance • 2 months ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

SAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, tod... Full story

Yahoo Finance • 3 months ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announc... Full story

Yahoo Finance • 3 months ago

Sagimet Biosciences GAAP EPS of -$0.32 beats by $0.21

* Sagimet Biosciences press release [https://seekingalpha.com/pr/20199186-sagimet-biosciences-reports-second-quarter-2025-financial-results-and-provides-corporate] (NASDAQ:SGMT [https://seekingalpha.com/symbol/SGMT]): Q2 GAAP EPS of -$0.... Full story

Yahoo Finance • 3 months ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being devel... Full story

Yahoo Finance • 4 months ago

Eli Lilly downgraded, Lyft upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Roth Capital upgraded Lyft (LYFT) to Buy... Full story

Yahoo Finance • 4 months ago

The Implied Analyst 12-Month Target For AVSC

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 5 months ago

Sagimet stock holds steady as JMP reiterates $31 price target

JMP Securities reiterated its Market Outperform rating and $31.00 price target on Sagimet Biosciences Inc (NASDAQ:SGMT), currently trading at $7.40, following positive Phase 3 acne data from the company’s Chinese partner Ascletis. Accord... Full story

Yahoo Finance • 6 months ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announc... Full story

Yahoo Finance • 8 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational New Drug (IND) application for FAS... Full story

Yahoo Finance • last year

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trad... Full story

Yahoo Finance • 2 years ago

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

SAN MATEO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announces the accept... Full story

Yahoo Finance • 2 years ago

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways,... Full story